Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

recruiting375%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_1

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT06065462
recruitingphase_1

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

NCT06012734
completedphase_2

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

NCT03027388
recruitingphase_1

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT03886662

Clinical Trials (4)

Showing 4 of 4 trials
NCT06065462Phase 1

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting
NCT06012734Phase 1

LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Recruiting
NCT03027388Phase 2

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Completed
NCT03886662Phase 1

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4